Literature DB >> 7447430

Comparative antimicrobial activity of O-demethylfortimicin A, a derivative of fortimicin A.

R L Girolami, J M Stamm.   

Abstract

The in vitro antimicrobial activity of O-demethylfortimicin A (ODMF), a derivative of fortimicin A, was compared with those of fortimicin A and gentamicin against a spectrum of 256 organisms. All three antibiotics were active in low concentrations against all strains of Enterobacteriaceae, Acinetobacter sp., and Staphylococcus aureus, with ODMF most active against Proteus mirabilis, indole-positive Proteus, and Providencia and gentamicin most active against other species. Activity of each of the antibiotics against group D streptococci was poor. The overall activity of ODMF was superior to that of fortimicin A for all groups of organisms examined and was most pronounced, approximately three-fold, against strains of Pseudomonas aeruginosa. Both ODMF and fortimicin A were resistant to the action of several aminoglycoside-inactivating enzymes, with the exception of 3-N-acetyltransferase-I. ODMF and fortimicin A showed similar rapid bactericidal effects at multiples of the minimum inhibitory concentration and equivalent synergistic activity against enterococci when combined with penicillin G. The combination of carbenicillin with ODMF, fortimicin A, or gentamicin was synergistic for approximately 80% of the P. aeruginosa strains tested. Inactivation of ODMF and fortimicin A when combined with carbenicillin in vitro was minimal or absent, whereas gentamicin was substantially inactivated under similar conditions. ODMF, fortimicin A, and gentamicin exhibited protective activity in mice infected with Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, S. aureus, or P. aeruginosa. Gentamicin was the most active, followed by ODMF and fortimicin A. The superior in vitro activity of ODMF compared with fortimicin A against P. aeruginosa was confirmed in vivo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7447430      PMCID: PMC284089          DOI: 10.1128/AAC.18.5.766

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Enzymatic acetylation of fortimicin A and seldomycin factor 5 by aminoglycoside 3-acetyltransferase I: [AAC(3)-I] of E. coli KY8348.

Authors:  S Sato; T Iida; R Okachi; K Shirahata; T Nara
Journal:  J Antibiot (Tokyo)       Date:  1977-11       Impact factor: 2.649

2.  Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin.

Authors:  J E McLaughlin; D S Reeves
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

3.  Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin.

Authors:  V T Andriole
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

4.  Laboratory and clinical conditions for gentamicin inactivation by carbenicillin.

Authors:  L J Riff; G G Jackson
Journal:  Arch Intern Med       Date:  1972-12

5.  Synergy of penicillin and gentamicin against Enterococci.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity.

Authors:  R M Kluge; H C Standiford; B Tatem; V M Young; S C Schimpff; W H Greene; F M Calia; R B Hornick
Journal:  Ann Intern Med       Date:  1974-11       Impact factor: 25.391

7.  Fortimicins A and B, new aminoglycoside antibiotics. IV. In vitro study of fortimicin A compared with other aminoglycosides.

Authors:  R L Girolami; J M Stamm
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

8.  Susceptibility of Pseudomonas aeruginosa to tobramycin or gentamicin alone and combined with carbenicillin.

Authors:  E L Anderson; P K Gramling; P R Vestal; W E Farrar
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

9.  Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.

Authors:  R N Jones; A L Barry; P C Fuchs; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

10.  Effect of time and concentration upon interaction between gentamicin, tobramycin, Netilmicin, or amikacin and carbenicillin or ticarcillin.

Authors:  L K Pickering; P Gearhart
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

View more
  4 in total

Review 1.  Aminoglycoside research 1975-1985: prospects for development of improved agents.

Authors:  K E Price
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

2.  Synthesis of 3-O-demethylfortimicins.

Authors:  J R Martin; P Johnson; J Tadanier; A Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of K-4619, a new semisynthetic aminoglycoside.

Authors:  Y Saino; Y Hattori; T Koshi; F Kobayashi; T Oda; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests.

Authors:  A L Barry; R N Jones; C Thornsberry; T L Gavan; E H Gerlach; H M Sommer
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.